Medtronic
(NYSE: MDT)
announced that it named Dr. Simona Zannetti as the GM of its Aortic business unit.
Zannetti previously spent 21 years at the medtech giant. She spent the last 16 months as SVP of clinical research at Penumbra, joining the interventional device maker in September 2022.
In a LinkedIn post today, Nina Goodheart, SVP and president, Structural Heart & Aortic at Medtronic, shared the news of Zannetti’s return.
“She is a familiar face to many of us and we’re so glad to have her back,” Goodheart wrote.
Among several roles at Medtronic over more than two decades, Zannetti most recently served as VP of clinical research and medical science for peripheral vascular health. She also had the post of VP of clinical research and the Office of Medical Affairs, Aortic, Peripheral and Venous for more than five years. From 2009 to 2015, she was VP of clinical research and the Office of Medical Affairs for Endovascular Innovation.
“After a great sixteen months at Penumbra where I worked alongside a fantastic team, I am excited to share that I am returning to Medtronic as General Manager for the Aortic business,” Zannetti said on LinkedIn. “I look forward to going back to my roots where my career began 23 years ago and to work with my friends at Medtronic.”
Goodheart said that, under Zannetti’s leadership at Medtronic, the company established endovascular treatment options as a standard of care for abdominal and thoracic disease.
“Her clinical experience will be invaluable to our work as we develop life-saving treatments for patients and drive market growth,” Goodheart said. “I look forward to partnering with Simona as she drives commercial excellence among the Aortic team and positions the business for success in the years to come.”